Targeting antibiotic resistance genes in vibrio cholerae using a phage-encoded crispr-CAS system to improve efficacy of phage prophylaxis
Ended Project Grant Awarded Last action
- Award ID
- R21AI156828
- Recipient
-
Phagepro, P.b.c. UEI KHNEFNHKMN84
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $944,977
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $766,336.00 Federal
- $178,641.00 Non-federal
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
- Abstract
- The incessant rise of multidrug resistance in bacterial pathogens has created a dire situation that necessitates development of new modalities for preventing and treating infectious diseases. Phage prophylaxis and phage therapy represent one such approach, since phages are not affected by antibiotic resistance phenotypes. The causative agent of cholera, vibrio cholerae, has become extensively drug resistant (XDR) in just the past decade due to indiscriminate and widespread antibiotic use in the community in low- and middle-income countries. We recently reported a phage product, comprised of virulent phages ICP1, ICP2 and ICP3, that effectively prevents cholera in animal models, which could be used to reduce infection rates those at-risk. However, that work used an antibiotic-sensitive, pre-1980 strain of V. Cholerae. Here, we seek to test two hypotheses that, if substantiated, could dramatically improve phage prophylaxis for cholera and would lend itself to improving phage products for other diseases caused by multidrug-resistant bacteria. The first hypothesis is that incorporating crispr spacers into ICP1, which specifically target antibiotic resistance genes in XDR V. Cholerae, can improve the ability of ICP1 to kill these strains both in vitro and in animal models, thereby better protecting the animals from infection. The second hypothesis is that by targeting antibiotic resistance genes for cleavage by crispr-CAS, we can dramatically reduce their frequencies of horizontal gene transfer.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $204,527 | $0 | |
| Amendment | $204,527 | $0 | |
| Amendment | $178,641 | $0 | |
| Original award | $178,641 | $178,641 |
Quick answers
Who received award R21AI156828?
R21AI156828 was awarded to Phagepro, P.b.c. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 1, 2021.
How much is award R21AI156828 worth?
$944,977 has been obligated on R21AI156828: $766,336 in federal funding and $178,641 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award